Cardiovascular Systems recently appointed Dr. Jeffrey Chambers as the company's new chief medical officer, as the company continues to build its product pipeline for interventional cardiology.
Chambers was the primary investigator for the Orbit II study, which supported premarket approval for the use of orbital atherectomy in coronary arteries. He also served as a consultant in connection with Cardiovascular Systems' product development, quality assurance, medical affairs, and clinical research.
Chambers received his medical degree from Wayne State University and completed his residency in and fellowships at the University of Minnesota. He has been with the Metropolitan Heart and Vascular Institute since 1995. Chambers is also a fellow at the American College of Cardiology and a member of the Society for Cardiovascular Angiography and Interventions.
